{
 "page": "https://jabbitapp.com/research/food-noise-coming-back-ozempic-wegovy-zepbound-retatrutide.html",
 "generated": "2026-10-20",
 "method": "ClinicalTrials.gov API v2 query.term searches for \"food noise\" and \"Food Noise Questionnaire\" (27 unique studies), hand-categorized; registry results of NCT05548647 (STABLE Wt Loss); text scan of 9 current DailyMed GLP-1 labels; PubMed \"food noise\"[tiab] search.",
 "ctgov_pulled": "2026-10-20T05:58-04:00",
 "ctgov_query_counts": {
  "\"food noise\"": 27,
  "\"Food Noise Questionnaire\"": 20,
  "\"food chatter\"": 0,
  "\"food preoccupation\" AND (semaglutide OR tirzepatide OR retatrutide OR liraglutide OR GLP-1)": 3
 },
 "studies_total": 27,
 "by_category": {
  "new obesity drug trial (industry, randomized vs placebo)": 8,
  "people taking approved GLP-1 drugs (observational, add-on or stop/restart)": 13,
  "questionnaire or data-method development": 3,
  "other, no GLP-1 drug": 3
 },
 "results_posted": [
  "NCT06315907"
 ],
 "first_posted_earliest": "2024-03-18",
 "first_posted_in_2026": 17,
 "lilly_or_novo_randomized_trials_with_food_noise_outcome": [],
 "studies": [
  {
   "nct": "NCT07284875",
   "category": "new obesity drug trial (industry, randomized vs placebo)",
   "title": "Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes",
   "sponsor": "Kailera",
   "sponsor_class": "INDUSTRY",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "PHASE3"
   ],
   "enrollment": 2530,
   "status": "ACTIVE_NOT_RECRUITING",
   "first_posted": "2025-12-16",
   "start": "2025-12-18",
   "primary_completion": "2028-02",
   "results_posted": false,
   "drug": "ribupatide (Kailera)",
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Change From Baseline in Food Noise Questionnaire (FNQ) Score",
     "time_frame": "Baseline, Week 76"
    }
   ]
  },
  {
   "nct": "NCT07284901",
   "category": "new obesity drug trial (industry, randomized vs placebo)",
   "title": "Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes",
   "sponsor": "Kailera",
   "sponsor_class": "INDUSTRY",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "PHASE3"
   ],
   "enrollment": 1270,
   "status": "ACTIVE_NOT_RECRUITING",
   "first_posted": "2025-12-16",
   "start": "2026-01-12",
   "primary_completion": "2028-03-27",
   "results_posted": false,
   "drug": "ribupatide (Kailera)",
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Change From Baseline in Food Noise Questionnaire (FNQ) Score",
     "time_frame": "Baseline, Week 76"
    }
   ]
  },
  {
   "nct": "NCT07284979",
   "category": "new obesity drug trial (industry, randomized vs placebo)",
   "title": "Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes",
   "sponsor": "Kailera",
   "sponsor_class": "INDUSTRY",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "PHASE3"
   ],
   "enrollment": 1270,
   "status": "ACTIVE_NOT_RECRUITING",
   "first_posted": "2025-12-16",
   "start": "2025-12-30",
   "primary_completion": "2028-03",
   "results_posted": false,
   "drug": "ribupatide vs semaglutide (Kailera)",
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Change From Baseline in Food Noise Questionnaire (FNQ) Score",
     "time_frame": "Baseline, Week 76"
    }
   ]
  },
  {
   "nct": "NCT07311850",
   "category": "new obesity drug trial (industry, randomized vs placebo)",
   "title": "Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity",
   "sponsor": "Pfizer",
   "sponsor_class": "INDUSTRY",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "PHASE3"
   ],
   "enrollment": 3578,
   "status": "ACTIVE_NOT_RECRUITING",
   "first_posted": "2025-12-31",
   "start": "2025-12-19",
   "primary_completion": "2027-09-21",
   "results_posted": false,
   "drug": "MET097 (Pfizer)",
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Change from baseline in Food Noise Questionnaire (FNQ)",
     "time_frame": "Baseline (Day 0) to Week 64 and Week 84"
    }
   ]
  },
  {
   "nct": "NCT07400653",
   "category": "new obesity drug trial (industry, randomized vs placebo)",
   "title": "A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)",
   "sponsor": "Pfizer",
   "sponsor_class": "INDUSTRY",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "PHASE3"
   ],
   "enrollment": 1078,
   "status": "ACTIVE_NOT_RECRUITING",
   "first_posted": "2026-02-10",
   "start": "2026-02-24",
   "primary_completion": "2027-10-12",
   "results_posted": false,
   "drug": "PF-08653944 (Pfizer)",
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Change from Baseline in Food Noise Questionnaire (FNQ)",
     "time_frame": "Baseline, Week 64 and 84"
    }
   ]
  },
  {
   "nct": "NCT07595549",
   "category": "new obesity drug trial (industry, randomized vs placebo)",
   "title": "A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity",
   "sponsor": "Pfizer",
   "sponsor_class": "INDUSTRY",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "PHASE3"
   ],
   "enrollment": 954,
   "status": "RECRUITING",
   "first_posted": "2026-05-19",
   "start": "2026-06-10",
   "primary_completion": "2028-05-04",
   "results_posted": false,
   "drug": "berobenatide, PF-08653944 (Pfizer)",
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Change from Baseline in Food Noise Questionnaire (FNQ) total score",
     "time_frame": "Baseline, Week 72"
    }
   ]
  },
  {
   "nct": "NCT07310901",
   "category": "new obesity drug trial (industry, randomized vs placebo)",
   "title": "A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity",
   "sponsor": "Corbus Pharmaceuticals Inc.",
   "sponsor_class": "INDUSTRY",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "PHASE1"
   ],
   "enrollment": 254,
   "status": "COMPLETED",
   "first_posted": "2025-12-30",
   "start": "2025-12-04",
   "primary_completion": "2026-08-03",
   "results_posted": false,
   "drug": "CRB-913 (Corbus)",
   "food_noise_outcomes": [
    {
     "type": "other",
     "measure": "Part 2: To evaluate changes in food noise",
     "time_frame": "Day 1 to 28 days post final dose"
    }
   ]
  },
  {
   "nct": "NCT07837973",
   "category": "new obesity drug trial (industry, randomized vs placebo)",
   "title": "Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss",
   "sponsor": "Alveus Therapeutics, Inc.",
   "sponsor_class": "INDUSTRY",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "PHASE2"
   ],
   "enrollment": 220,
   "status": "RECRUITING",
   "first_posted": "2026-09-24",
   "start": "2026-08-10",
   "primary_completion": "2027-08-24",
   "results_posted": false,
   "drug": "ALV-100 (Alveus)",
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Effect of ALV-100 vs. placebo on food noise as assessed by the Food Noise Questionnaire (FNQ)",
     "time_frame": "24-36 weeks"
    }
   ]
  },
  {
   "nct": "NCT06843512",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication",
   "sponsor": "Penn State University",
   "sponsor_class": "OTHER",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 25,
   "status": "RECRUITING",
   "first_posted": "2025-02-25",
   "start": "2025-07-15",
   "primary_completion": "2026-12",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Change in Baseline Weight Watchers Food Noise Score at 3 Months",
     "time_frame": "Baseline and 3 months"
    }
   ]
  },
  {
   "nct": "NCT07027995",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "Food and Fitness With Medicine (FFWM)",
   "sponsor": "Ohio State University",
   "sponsor_class": "OTHER",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "NA"
   ],
   "enrollment": 200,
   "status": "RECRUITING",
   "first_posted": "2025-06-19",
   "start": "2026-01-14",
   "primary_completion": "2028-11",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Food Noise",
     "time_frame": "0, 12, 24 and weeks"
    }
   ]
  },
  {
   "nct": "NCT07387796",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation",
   "sponsor": "The University of Texas at Dallas",
   "sponsor_class": "OTHER",
   "study_type": "INTERVENTIONAL",
   "allocation": "NA",
   "phases": [
    "NA"
   ],
   "enrollment": 40,
   "status": "RECRUITING",
   "first_posted": "2026-02-04",
   "start": "2026-10",
   "primary_completion": "2028-02",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Change From Baseline in Intrusive Food-Related Thoughts.",
     "time_frame": "Baseline (on tirzepatide), 3-4 weeks of discontinuation, and 6-8 weeks of re-initiation"
    }
   ]
  },
  {
   "nct": "NCT07404150",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "Lifestyle Program Focused on Nourishment, Well-Being, and Health Behaviors in Women With Obesity",
   "sponsor": "Heather Conradson",
   "sponsor_class": "OTHER",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 60,
   "status": "ENROLLING_BY_INVITATION",
   "first_posted": "2026-02-11",
   "start": "2026-01-12",
   "primary_completion": "2027-06-15",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "primary",
     "measure": "Percent weight change and internalized weight bias (WBIS)",
     "time_frame": "18 months"
    }
   ]
  },
  {
   "nct": "NCT07480109",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "Increased Dietary Protein Intake During GLP-1 Medication Use (in Middle-aged Women With Overweight/Obesity)",
   "sponsor": "University of Texas at Austin",
   "sponsor_class": "OTHER",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "NA"
   ],
   "enrollment": 75,
   "status": "RECRUITING",
   "first_posted": "2026-03-18",
   "start": "2026-06-01",
   "primary_completion": "2027-06-01",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Food Noise",
     "time_frame": "Baseline, 2 week, 4 week, 6 week, 8 week, 10 week, 12 weeks"
    }
   ]
  },
  {
   "nct": "NCT07505134",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "Exploring the Influence of Glucagon-like Peptide -1 (GLP-1) Medications on Food Cravings, Food Selection, and Food Intake Following Exposure to Food Advertisements",
   "sponsor": "Penn State University",
   "sponsor_class": "OTHER",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "NA"
   ],
   "enrollment": 50,
   "status": "NOT_YET_RECRUITING",
   "first_posted": "2026-04-01",
   "start": "2026-09",
   "primary_completion": "2026-12",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Changes in food noise since being on medication questionnaire",
     "time_frame": "Baseline"
    }
   ]
  },
  {
   "nct": "NCT07588984",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study",
   "sponsor": "Noom Inc.",
   "sponsor_class": "INDUSTRY",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 2310,
   "status": "NOT_YET_RECRUITING",
   "first_posted": "2026-05-15",
   "start": "2026-04-30",
   "primary_completion": "2029-05",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "other",
     "measure": "Change in food noise",
     "time_frame": "Baseline, months 4, 8, 12 (and 18, 24 for GLP-1 arms)"
    }
   ]
  },
  {
   "nct": "NCT07611201",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "The Effects of GLP-1 Receptor Agonists on Chemosensory Function and Ingestive Behavior",
   "sponsor": "Purdue University",
   "sponsor_class": "OTHER",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 90,
   "status": "COMPLETED",
   "first_posted": "2026-05-28",
   "start": "2025-02-20",
   "primary_completion": "2026-05-04",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Questionnaire-Based Measures of Food Cravings, Food Cue Responsivity, Food Noise, and Eating Behavior",
     "time_frame": "During study participation, up to 2 weeks"
    }
   ]
  },
  {
   "nct": "NCT07636395",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "Eating Behaviour Before, During, and After Obesity Medication",
   "sponsor": "University College Dublin",
   "sponsor_class": "OTHER",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 30,
   "status": "RECRUITING",
   "first_posted": "2026-06-09",
   "start": "2026-05-25",
   "primary_completion": "2026-08-25",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": []
  },
  {
   "nct": "NCT07701460",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1",
   "sponsor": "Tufts University",
   "sponsor_class": "OTHER",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "NA"
   ],
   "enrollment": 200,
   "status": "NOT_YET_RECRUITING",
   "first_posted": "2026-07-14",
   "start": "2026-10-15",
   "primary_completion": "2028-01-31",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "other",
     "measure": "Food Noise",
     "time_frame": "12-months"
    }
   ]
  },
  {
   "nct": "NCT07743567",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "Gestational Response, Outcomes, and Weight After GLP-1 Use",
   "sponsor": "University of Kansas Medical Center",
   "sponsor_class": "OTHER",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 400,
   "status": "RECRUITING",
   "first_posted": "2026-08-04",
   "start": "2026-04-13",
   "primary_completion": "2028-04",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": []
  },
  {
   "nct": "NCT07829016",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "GLP-1 Impacts on Weight Management",
   "sponsor": "University of California, San Francisco",
   "sponsor_class": "OTHER",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 100,
   "status": "NOT_YET_RECRUITING",
   "first_posted": "2026-09-18",
   "start": "2026-10-20",
   "primary_completion": "2029-09-01",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Change in Food Noise",
     "time_frame": "Baseline to 4 and 6 months"
    }
   ]
  },
  {
   "nct": "NCT07850765",
   "category": "people taking approved GLP-1 drugs (observational, add-on or stop/restart)",
   "title": "Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets",
   "sponsor": "Novo Nordisk A/S",
   "sponsor_class": "INDUSTRY",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 1260,
   "status": "COMPLETED",
   "first_posted": "2026-09-30",
   "start": "2026-08-28",
   "primary_completion": "2026-08-31",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "primary",
     "measure": "Change in Food Noise Questionnaire (FNQ) score",
     "time_frame": "At data capture (Day 1)"
    }
   ]
  },
  {
   "nct": "NCT06315907",
   "category": "questionnaire or data-method development",
   "title": "Development and Validation of a Brief Food Noise Questionnaire",
   "sponsor": "Pennington Biomedical Research Center",
   "sponsor_class": "OTHER",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 400,
   "status": "COMPLETED",
   "first_posted": "2024-03-18",
   "start": "2024-04-25",
   "primary_completion": "2024-05-10",
   "results_posted": true,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "primary",
     "measure": "Scores on the Food Noise Questionnaire",
     "time_frame": "The Food Noise Questionnaire (FNQ) was completed once as part of a larger online survey. The entire online survey was completed in approximately 30 to 45 minutes, and the FNQ items were completed in approximately 5 to 10 minutes."
    }
   ]
  },
  {
   "nct": "NCT07762430",
   "category": "questionnaire or data-method development",
   "title": "Food Noise Survey Development and Validation in Hindi and English-Speaking Adults",
   "sponsor": "Diabetes Foundation, India",
   "sponsor_class": "OTHER",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 300,
   "status": "NOT_YET_RECRUITING",
   "first_posted": "2026-08-13",
   "start": "2026-09-01",
   "primary_completion": "2027-09-30",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "primary",
     "measure": "Ro Allison Indiana Dhurandhar Food Noise Inventory (RAID-FN)",
     "time_frame": "1 Year"
    }
   ]
  },
  {
   "nct": "NCT07759544",
   "category": "questionnaire or data-method development",
   "title": "I-OPERA: A European Study Testing a New Way to Do Health Research.",
   "sponsor": "IQVIA RDS Spain, SL",
   "sponsor_class": "INDUSTRY",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 105,
   "status": "NOT_YET_RECRUITING",
   "first_posted": "2026-08-12",
   "start": "2026-11",
   "primary_completion": "2027-02",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "primary",
     "measure": "This study will collect a focused set of self-reported descriptive and participant-reported measures relevant to the real-world experience of adults with obesity.",
     "time_frame": "Retrospective clinical data covering up to approximately five years prior to enrolment."
    }
   ]
  },
  {
   "nct": "NCT07018830",
   "category": "other, no GLP-1 drug",
   "title": "Multicomponent Program for Addressing Cognition in Rural Communities",
   "sponsor": "Pennington Biomedical Research Center",
   "sponsor_class": "OTHER",
   "study_type": "INTERVENTIONAL",
   "allocation": "NA",
   "phases": [
    "NA"
   ],
   "enrollment": 11,
   "status": "COMPLETED",
   "first_posted": "2025-06-13",
   "start": "2025-04-22",
   "primary_completion": "2025-06-22",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "The Food Noise Questionnaire",
     "time_frame": "3 months"
    }
   ]
  },
  {
   "nct": "NCT07245914",
   "category": "other, no GLP-1 drug",
   "title": "A Consumer Health Study Evaluating the Impact of Pivit on Weight Loss and Appetite in Overweight Individuals",
   "sponsor": "Olfactive Biosolutions, Inc.",
   "sponsor_class": "INDUSTRY",
   "study_type": "OBSERVATIONAL",
   "allocation": null,
   "phases": null,
   "enrollment": 125,
   "status": "ACTIVE_NOT_RECRUITING",
   "first_posted": "2025-11-24",
   "start": "2025-07-30",
   "primary_completion": "2026-01-26",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "secondary",
     "measure": "Gastrointestinal Symptoms",
     "time_frame": "12 weeks; 3 months"
    }
   ]
  },
  {
   "nct": "NCT07862153",
   "category": "other, no GLP-1 drug",
   "title": "Digital Acceptance & Commitment Therapy for Weight Self-stigma",
   "sponsor": "Utah State University",
   "sponsor_class": "OTHER",
   "study_type": "INTERVENTIONAL",
   "allocation": "RANDOMIZED",
   "phases": [
    "PHASE2"
   ],
   "enrollment": 100,
   "status": "NOT_YET_RECRUITING",
   "first_posted": "2026-10-07",
   "start": "2026-10-05",
   "primary_completion": "2027-12-01",
   "results_posted": false,
   "drug": null,
   "food_noise_outcomes": [
    {
     "type": "other",
     "measure": "Food Noise Questionnaire",
     "time_frame": "Baseline, 2-week, and 4-week follow up"
    }
   ]
  }
 ],
 "stable_nct05548647": {
  "started": {
   "FG000": 48,
   "FG001": 72,
   "FG002": 0,
   "FG003": 0
  },
  "completed_week60": {
   "FG000": 26,
   "FG001": 61,
   "FG002": 0,
   "FG003": 0
  },
  "outcomes": {
   "lunch_kcal": {
    "title": "Study 1 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)",
    "unit": "kcal",
    "values": {
     "Week 20": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": -75.1,
      "Behavioral Treatment + Medication (Weeks 0-60": -367.0
     },
     "Week 40": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": -76.8,
      "Behavioral Treatment + Medication (Weeks 0-60": -317.0
     },
     "Week 60": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": 69.6,
      "Behavioral Treatment + Medication (Weeks 0-60": -200.0
     }
    },
    "analyses": [
     {
      "p": "<0.0001",
      "diff": 291.9,
      "ci": [
       164.0,
       419.8
      ]
     },
     {
      "p": "0.0078",
      "diff": 240.2,
      "ci": [
       65.2,
       415.3
      ]
     },
     {
      "p": "0.0019",
      "diff": 269.5,
      "ci": [
       102.8,
       436.1
      ]
     }
    ]
   },
   "fasting_appetite": {
    "title": "Study 1 Laboratory-based Appetite Measured as a Composite of Visual Analogue Scale Ratings (Hunger, Fullness, Satiety, Prospective Consumption) When Fasting",
    "unit": "mm",
    "values": {
     "Week 20": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": 3.8,
      "Behavioral Treatment + Medication (Weeks 0-60": 16.0
     },
     "Week 40": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": -0.5,
      "Behavioral Treatment + Medication (Weeks 0-60": 6.9
     },
     "Week 60": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": 1.4,
      "Behavioral Treatment + Medication (Weeks 0-60": 2.3
     }
    },
    "analyses": [
     {
      "p": "0.0004",
      "diff": -12.1,
      "ci": [
       -18.6,
       -5.6
      ]
     },
     {
      "p": "0.0784",
      "diff": -7.4,
      "ci": [
       -15.6,
       0.9
      ]
     },
     {
      "p": null,
      "diff": -1.0,
      "ci": [
       -8.9,
       7.0
      ]
     }
    ]
   },
   "hunger_pastweek": {
    "title": "Study 1 Past-week Hunger as Measured Using the Control of Eating Questionnaire (COEQ)",
    "unit": "mm",
    "values": {
     "Week 20": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": -14.4,
      "Behavioral Treatment + Medication (Weeks 0-60": -31.9
     },
     "Week 40": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": -14.6,
      "Behavioral Treatment + Medication (Weeks 0-60": -25.4
     },
     "Week 60": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": -10.6,
      "Behavioral Treatment + Medication (Weeks 0-60": -17.4
     }
    },
    "analyses": [
     {
      "p": "0.0004",
      "diff": 17.5,
      "ci": [
       7.9,
       27.1
      ]
     },
     {
      "p": "0.061",
      "diff": 10.8,
      "ci": [
       -0.5,
       22.2
      ]
     },
     {
      "p": null,
      "diff": 6.8,
      "ci": [
       -3.5,
       17.2
      ]
     }
    ]
   },
   "preoccupation_pastweek": {
    "title": "Study 1 Past-week Food Preoccupation as Measured Using the Control of Eating Questionnaire (COEQ)",
    "unit": "mm",
    "values": {
     "Week 20": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": -14.7,
      "Behavioral Treatment + Medication (Weeks 0-60": -29.6
     },
     "Week 40": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": -17.0,
      "Behavioral Treatment + Medication (Weeks 0-60": -24.9
     },
     "Week 60": {
      "Behavioral Treatment + Placebo (Weeks 0-60)": -13.1,
      "Behavioral Treatment + Medication (Weeks 0-60": -22.4
     }
    },
    "analyses": [
     {
      "p": "0.0014",
      "diff": 14.9,
      "ci": [
       6.0,
       23.9
      ]
     },
     {
      "p": "0.111",
      "diff": 7.9,
      "ci": [
       -1.8,
       17.6
      ]
     },
     {
      "p": null,
      "diff": 9.3,
      "ci": [
       0.9,
       17.8
      ]
     }
    ]
   },
   "s2_lunch": {
    "title": "Study 2 Ad Libitum Energy Intake (kcal) During a Buffet Lunch Meal (4 Hrs After Standardized Breakfast)",
    "unit": "kcal",
    "values": {
     "endpoint": {
      "Continuous Placebo (Weeks 60-72)": 1073.0,
      "Medication (Semaglutide) Switched to Placebo ": 951.8,
      "Continued Medication (Semaglutide) (Weeks 60-": 657.7
     }
    },
    "analyses": [
     {
      "p": "0.1513",
      "diff": 121.2,
      "ci": [
       -46.0,
       288.4
      ]
     }
    ]
   },
   "s2_hunger": {
    "title": "Study 2 Past-week Hunger as Measured Using the Control of Eating Questionnaire (COEQ)",
    "unit": "mm",
    "values": {
     "endpoint": {
      "Continuous Placebo (Weeks 60-72)": 48.5,
      "Medication (Semaglutide) Switched to Placebo ": 63.6,
      "Continued Medication (Semaglutide) (Weeks 60-": 38.5
     }
    },
    "analyses": [
     {
      "p": "0.0196",
      "diff": -15.1,
      "ci": [
       -27.6,
       -2.5
      ]
     }
    ]
   },
   "s2_preoccupation": {
    "title": "Study 2 Past-week Food Preoccupation as Measured Using the Control of Eating Questionnaire (COEQ)",
    "unit": "mm",
    "values": {
     "endpoint": {
      "Continuous Placebo (Weeks 60-72)": 42.7,
      "Medication (Semaglutide) Switched to Placebo ": 62.9,
      "Continued Medication (Semaglutide) (Weeks 60-": 26.4
     }
    },
    "analyses": [
     {
      "p": "0.0017",
      "diff": -20.3,
      "ci": [
       -32.6,
       -8.0
      ]
     }
    ]
   },
   "s2_weight": {
    "title": "Study 2 Body Weight (kg)",
    "unit": "kg",
    "values": {
     "endpoint": {
      "Continuous Placebo (Weeks 60-72)": 98.3,
      "Medication (Semaglutide) Switched to Placebo ": 88.9,
      "Continued Medication (Semaglutide) (Weeks 60-": 85.3
     }
    },
    "analyses": [
     {
      "p": "<0.001",
      "diff": 9.4,
      "ci": [
       4.5,
       14.3
      ]
     }
    ]
   }
  },
  "note": "Mean differences are semaglutide minus placebo (registry sign conventions vary by measure); missing data imputed jump-to-reference; p-values not reported at week 60 under the hierarchical testing in the registry record."
 },
 "labels": {
  "foundayo": {
   "version": "10",
   "effective": "20260729",
   "gastric_emptying_fades": [
    "The delay is largest after the first dose and diminishes over time.",
    "The effect diminished after repeated dosing of FOUNDAYO 17.",
    "The gastric emptying delay effect of orforglipron on acetaminophen C max was largest after the first dose of FOUNDAYO 0."
   ],
   "backup_contraception_after_each_escalation": [
    "1 ) Females of Reproductive Potential: Advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation and for 30 days after each dose escalation.",
    "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation with FOUNDAYO and for 30 days after each dose escalation [see Drug Interactions ( 7.",
    "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation with FOUNDAYO and for 30 days after each dose escalation.",
    "Because delayed gastric emptying may affect the absorption of oral medications, advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 30 days after initiation with FOUNDAYO and for 30 days after each dose escalation [see Drug Interactions ( 7."
   ],
   "appetite_statement": [
    "This effect is likely mediated by decreased appetite."
   ],
   "mentions_food_noise": false,
   "mentions_craving": false
  },
  "mounjaro": {
   "version": "40",
   "effective": "20260827",
   "gastric_emptying_fades": [
    "The delay is largest after the first dose and this effect diminishes over time.",
    "The impact of tirzepatide on gastric emptying was greatest after a single dose of 5 mg and diminished after subsequent doses.",
    "This delay is largest after the first dose and diminishes over time."
   ],
   "backup_contraception_after_each_escalation": [
    "1 ) Females of Reproductive Potential: Advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.",
    "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO [see Drug Interactions ( 7.",
    "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO."
   ],
   "appetite_statement": [],
   "mentions_food_noise": false,
   "mentions_craving": false
  },
  "ozempic": {
   "version": "20",
   "effective": "20260601",
   "gastric_emptying_fades": [],
   "backup_contraception_after_each_escalation": [],
   "appetite_statement": [],
   "mentions_food_noise": false,
   "mentions_craving": false
  },
  "rybelsus": {
   "version": "14",
   "effective": "20260130",
   "gastric_emptying_fades": [],
   "backup_contraception_after_each_escalation": [],
   "appetite_statement": [],
   "mentions_food_noise": false,
   "mentions_craving": false
  },
  "saxenda": {
   "version": "22",
   "effective": "20260225",
   "gastric_emptying_fades": [],
   "backup_contraception_after_each_escalation": [],
   "appetite_statement": [
    "2 Pharmacodynamics Liraglutide lowers body weight through decreased calorie intake."
   ],
   "mentions_food_noise": false,
   "mentions_craving": false
  },
  "trulicity": {
   "version": "62",
   "effective": "20260616",
   "gastric_emptying_fades": [
    "The delay is largest after the first dose and diminishes with subsequent doses."
   ],
   "backup_contraception_after_each_escalation": [],
   "appetite_statement": [],
   "mentions_food_noise": false,
   "mentions_craving": false
  },
  "victoza": {
   "version": "31",
   "effective": "20251014",
   "gastric_emptying_fades": [],
   "backup_contraception_after_each_escalation": [],
   "appetite_statement": [],
   "mentions_food_noise": false,
   "mentions_craving": false
  },
  "wegovy": {
   "version": "19",
   "effective": "20260618",
   "gastric_emptying_fades": [],
   "backup_contraception_after_each_escalation": [],
   "appetite_statement": [
    "The effects are likely mediated by affecting appetite."
   ],
   "mentions_food_noise": false,
   "mentions_craving": false
  },
  "zepbound": {
   "version": "40",
   "effective": "20260828",
   "gastric_emptying_fades": [
    "The delay is largest after the first dose and this effect diminishes over time.",
    "The impact of tirzepatide on gastric emptying was greatest after a single dose of 5 mg and diminished after subsequent doses.",
    "This delay is largest after the first dose and diminishes over time."
   ],
   "backup_contraception_after_each_escalation": [
    "1 ) Females of Reproductive Potential: Advise females using oral contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation.",
    "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation [see Drug Interactions ( 7.",
    "Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation."
   ],
   "appetite_statement": [
    "The effects are likely mediated by affecting appetite."
   ],
   "mentions_food_noise": false,
   "mentions_craving": false
  }
 },
 "labels_gastric_emptying_fades": [
  "foundayo",
  "mounjaro",
  "trulicity",
  "zepbound"
 ],
 "pubmed_food_noise_tiab": {
  "count": 40,
  "pmids": [
   "42897102",
   "42801078",
   "42782188",
   "42772688",
   "42738994",
   "42678482",
   "42641845",
   "42587021",
   "42575863",
   "42392316",
   "42320798",
   "42306816",
   "42247231",
   "42233931",
   "42223191",
   "42217114",
   "42125907",
   "42083883",
   "42073972",
   "42049707",
   "41997909",
   "41926561",
   "41676959",
   "41667418",
   "41502834",
   "41470865",
   "41420306",
   "41249456",
   "41237290",
   "41101555",
   "40685549",
   "40628707",
   "40259493",
   "39828656",
   "39819745",
   "39762910",
   "39017507",
   "38928616",
   "38004203",
   "3417934"
  ],
  "searched": "2026-10-20"
 },
 "x_counts": {
  "query_1": "\"food noise\" lang:en -is:retweet",
  "utc_days_2026_10_13_to_19": [
   117,
   139,
   97,
   127,
   72,
   68,
   161
  ],
  "note_1": "Oct 13 from 09:52 UTC",
  "query_2": "\"food noise\" with retatrutide/reta/tirzepatide/zepbound/mounjaro/semaglutide/ozempic/wegovy/glp1/glp-1/glp/tirz/sema/peptide, -is:retweet, any language",
  "utc_days_2026_10_13_to_19_q2": [
   20,
   31,
   25,
   36,
   15,
   12,
   41
  ],
  "pulled": "2026-10-20 ~5:55 AM ET"
 }
}